Glycophorin A is the major glycoprotein on the human erythrocyte surface and contains one N-glycan and multiple O-glycans. Glycophorin B, a highly homologous glycoprotein on human erythrocytes, contains only O-glycans. Although appropriate glycosylation is crucial for cell surface expression of glycophorin A, the mechanism responsible for this effect is not understood. Glycophorin A and B are important in the practice of transfusion medicine since they carry multiple human blood group antigens, and antibodies to these antigens can cause hemolytic transfusion reactions, hemolytic disease of the newborn,a nd autoimmune hemolytic anemia. However, there have been few studies examining the fine specificity of binding of human polyclonal and mouse monoclonal antibodies to these molecules. Glycophorins A and B are also of medical importance because they serve as erythrocyte surface receptors for the invasion of Plasmodium falciparum malaria merozoites. Due to the difficulty in obtaining mutant glycophorin molecules with defined variaitons in amino acid sequence and oligosaccharide structure, a detailed understanding of this host cell- parasite interaction is not yet available. The goals of the current proposal are to study the cell biology, immunology, and receptor function of the human blood group glycophorin antigens by: 1. determining the role that the N-glycans and O-glycans play in intracellular transport of glycophorin A. 2. using recombinant DNA approaches to examine the murine and human immune response to glycophorins A and B, and 3. determining the peptide and carbohydrate portions of glycophorins A and B that are recognized by human malaria parasites. These goals will be achieved by using a series of stably transfected cell lines expressing cDNA of wild type or variant glycophorin A or B. New mutant glycophorin A and B cDNAs will be constructed by site-directed mutagenesis. B=y expressing the cDNAs in both normal Chinese hamster ovary fibroblasts and those with defects in glycosylation, it is possible to create variant glycophorins that differ in both amino acid and carbohydrate sequence. Phage display libraries will be constructed to examine the murine immune response to glycophorin A. This will determine whether the immune response is restricted and will also result in athe construction of new clinically useful serological reagents. In summary, these studies will result in greater understanding of the cell biology, immunology, and receptor function of glycophorins A and B.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
1P50HL054516-01
Application #
5214315
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1996
Total Cost
Indirect Cost
Siegel, Don L (2008) Translational applications of antibody phage display. Immunol Res 42:118-31
Siegel, Don L (2007) Phage display-based molecular methods in immunohematology. Transfusion 47:89S-94S
Xie, Kefang; Song, Shuh Chyung; Spitalnik, Steven L et al. (2005) Crystallographic analysis of the NNA7 Fab and proposal for the mode of human blood-group recognition. Acta Crystallogr D Biol Crystallogr 61:1386-94
Siegel, Don L (2005) Developing phage display tools for use in transfusion medicine. Transfusion 45:100S-108S
Song, Shuh Chyung; Xie, Kefang; Czerwinski, Marcin et al. (2004) Purification, crystallization and X-ray diffraction analysis of a recombinant Fab that recognizes a human blood-group antigen. Acta Crystallogr D Biol Crystallogr 60:788-91
Czerwinski, Marcin; Krop-Watorek, Anna; Lisowska, Elwira et al. (2002) Construction of dimeric F(ab) useful in blood group serology. Transfusion 42:257-64
Young, Donald S; Sachais, Bruce S; Jefferies, Leigh C (2002) Effect of disease complications on hospital costs. Clin Chem 48:140-9
Honczarenko, Marek; Le, Yi; Glodek, Aleksandra M et al. (2002) CCR5-binding chemokines modulate CXCL12 (SDF-1)-induced responses of progenitor B cells in human bone marrow through heterologous desensitization of the CXCR4 chemokine receptor. Blood 100:2321-9
Siegel, D L (2002) Recombinant monoclonal antibody technology. Transfus Clin Biol 9:15-22
Jefferies, L C; Sachais, B S; Young, D S (2001) Blood transfusion costs by diagnosis-related groups in 60 university hospitals in 1995. Transfusion 41:522-9

Showing the most recent 10 out of 26 publications